Method for Preparing Polydopamine Nanomotor Using Urease and Use of Same
USPTO granted Patent US12599571B2 to POSTECH Research and Business Development Foundation for a biocompatible polydopamine nanomotor using urease. The nanomotor is designed to infiltrate bladder walls in biological environments and remain inside the bladder for extended periods. The patent includes 10 claims covering the preparation method and therapeutic applications.
National Survey of Health Information Exchange Organizations (HIO) - 60-Day Comment Request
HHS ONC is requesting public comment on a revised information collection for the National Survey of Health Information Exchange Organizations (HIO). The survey (OMB No. 0955-0019) collects data on HIO capabilities including technical standards adoption, information blocking perceptions, TEFCA connectivity, public health data exchange, and organizational demographics. This 3-year approval request revises a survey previously approved in 2022 and 2024, removing low-relevance questions and updating wording to align with current policy priorities. Comments are due June 22, 2026.
CMS-10950 Acute Hospital Care at Home Waiver Information Collection Request
CMS published a Paperwork Reduction Act notice announcing an opportunity for public comment on a new information collection request (OMB Control No. 0938-1384) related to the Acute Hospital Care at Home (AHCAH) waiver program. The collection covers submission requirements for hospitals seeking AHCAH waivers that allow at-home acute hospital-level care. To date, 433 hospitals have submitted waiver requests with 396 approved. Comments are due June 22, 2026.
Agency Information Collection Activities: Submission for OMB Review; Comment Request
CMS published a notice announcing two information collection requests under the Paperwork Reduction Act: (1) an extension of CMS-10242 covering Emergency Ambulance Transports and Beneficiary Signature requirements (affecting 10,278 respondents, 9,265,931 annual responses), and (2) a reinstatement of CMS-1771 covering Emergency and Foreign Hospital Services claims under 42 CFR 424.103. The notice invites public comment on burden estimates and information collection aspects. Comments must be received by the OMB desk officer by May 20, 2026.
APHIS Requests Extension of Information Collection Approval for Special Need Requests Under Plant Protection Act
APHIS is requesting a 3-year extension of OMB approval for information collection activities under the Plant Protection Act related to Special Need Requests (OMB Control No. 0579-0291). The collection allows states to request APHIS approval to impose prohibitions or restrictions on specific articles posing plant health risks, in addition to APHIS requirements. The estimated public burden is 160 hours per response, with one state government respondent expected annually.
NIEHS Partially Closed Meeting Notice - National Advisory Environmental Health Sciences Council
NIEHS published notice of a partially closed meeting of the National Advisory Environmental Health Sciences Council on June 24, 2026. The meeting includes open sessions on microplastics research, environmental health sciences programs, and health/weather research coordination. A closed session from 4:00-6:00 p.m. will review grant applications under FOIA exemption provisions. Interested persons may submit written comments or request to present oral comments to the committee.
National Institute of Dental and Craniofacial Research Advisory Council Meeting Notice
NIH's National Institute of Dental and Craniofacial Research announces a meeting of the National Advisory Dental and Craniofacial Research Council on May 19-20, 2026, in Bethesda, MD and virtual format. The closed session on May 19 will review grant applications; the open session on May 20 will include the Director's report and concept clearances. A backup meeting is scheduled for July 9, 2026.
National Institute of Neurological Disorders and Stroke Council Meeting Notice
The NIH National Institute of Neurological Disorders and Stroke has announced a public meeting of the National Advisory Neurological Disorders and Stroke Council on May 20, 2026, from 10:00 a.m. to 5:00 p.m. The virtual meeting will include reports from the Acting Director, program updates on HEAL and Small Business programs, and an overview of intramural activities. Interested persons may submit written comments to the Contact Person at least 10 days in advance of the meeting.
NCATS Advisory Council Meeting Notice May 21-22
The NIH National Center for Advancing Translational Sciences (NCATS) has published notice of its Advisory Council meeting scheduled for May 21-22, 2026. The closed session on May 21 will review grant applications, while the open session on May 22 will cover the Center Director's report, program updates, and concept clearances. The meeting will be held at NCI Shady Grove in Rockville, MD, with virtual access available.
NIH Clinical Center Research Hospital Board Meeting Notice
The NIH Office Director announces a hybrid meeting of the NIH Clinical Center Research Hospital Board on June 12, 2026, from 9:00 a.m. to 1:00 p.m. The meeting will be held at NIH Building 31, Conference Room 6C02 A & B, Bethesda, MD, and virtually via NIH Videocast. The agenda includes NIH and Clinical Center Leadership Announcements, an update from the CC Acting CEO on recent activities and organizational priorities, and other board business. The meeting is open to the public.
Center for Scientific Review Notice of 11 Closed Meetings
The National Institutes of Health published a notice announcing 11 closed meetings of the Center for Scientific Review in May 2026. The meetings will review and evaluate grant applications across various research areas including biomedical informatics, blood-brain barrier studies, bacterial virulence, and clinical trials. Meetings are closed to the public under the Federal Advisory Committee Act provisions.
Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting
The NIH announces a meeting of the Diabetes Mellitus Interagency Coordinating Committee (DMICC) on June 24, 2026, from 12:00 to 3:00 p.m. EDT. The virtual meeting will focus on 'Innovative Research Partnerships in Diabetic Retinal Disease: Insights and Opportunities' and is open to the public. Individuals interested in presenting oral comments must notify the contact person at least 5 days in advance.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review published a Federal Register notice announcing seven closed meetings scheduled between May 19 and June 9, 2026. The meetings involve Special Emphasis Panels and Integrated Review Groups reviewing grant applications and contract proposals for research including diabetes, infectious diseases, neurology, cancer, and clinical studies. Meetings are closed pursuant to the Government in the Sunshine Act to protect confidential trade secrets, commercial property, and personal information of grant applicants. The notice satisfies the Federal Advisory Committee Act requirement for advance notice of closed advisory committee meetings.
Potential New Indication for Testosterone Replacement Therapy
FDA announced it has reviewed published literature suggesting testosterone replacement therapy (TRT) may be safe and effective for treating low libido in men with decreased libido associated with idiopathic hypogonadism. The Agency encourages holders of approved TRT new drug applications to contact FDA by April 30, 2026, for information on submitting a supplemental NDA for this potential new indication.
Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators
FDA announced draft guidance providing a proposed compliance policy for respirators approved by CDC NIOSH under 42 CFR part 84, including surgical N95 respirators, PAPRs, reusable elastomeric respirators, and FFRs for general public use during public health emergencies. Once finalized, the guidance is intended to facilitate more efficient and effective use of resources consistent with least burdensome device policies.
Establishing Impurity Specifications for Antibiotics Draft Guidance
FDA announced availability of draft guidance titled 'Establishing Impurity Specifications for Antibiotics,' providing recommendations for establishing specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. The draft guidance applies to antibiotic drugs subject to approval under NDAs, ANDAs, and associated type II drug substance DMFs, as well as OTC monograph antibiotic drugs. Comments are due by June 22, 2026.
Qualitative Data Research Clearance Extension, OMB Control No. 0910-0891
The FDA published a notice under the Paperwork Reduction Act announcing an opportunity for public comment on extending OMB Control Number 0910-0891, the Generic Clearance for Qualitative Data to Support Social and Behavioral Research. The clearance covers submissions for qualitative data to support research related to food, dietary supplements, cosmetics, and animal food and feed. Comments must be submitted by June 16, 2026.
Variance Approval to VarsIQ Media
The FDA Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to VarsIQ Media. Variances are exemptions or waivers from specific regulatory requirements under the Federal Food, Drug, and Cosmetic Act. This approval modifies the applicable regulatory requirements for VarsIQ Media, allowing deviation from certain standard CDRH requirements.
VarsIQ Media Ohio Variance Application - CDRH
FDA's Center for Devices and Radiological Health (CDRH) received a variance application from VarsIQ Media seeking relief from specific FDA regulatory requirements. The application was filed under docket FDA-2026-V-3708-0001 in Ohio. No supporting documents are currently available for review on the regulatory portal. This filing represents a request for FDA to exercise regulatory flexibility under applicable medical device regulations.
FDA CTP Complaint Filed and Closed
FDA's Center for Tobacco Products (CTP) filed a complaint on April 16, 2026, which has since been closed. The document record indicates only that a complaint was filed and subsequently closed, with the full complaint content not available in the regulatory docket. No additional details regarding the nature of the complaint, parties involved, or any resulting enforcement actions are provided in the available metadata.
Animal Generic Drug User Fee Act Reauthorization; Public Meeting and Comment Request
FDA announces a virtual public meeting on May 27, 2026 regarding the Animal Generic Drug User Fee Act (AGDUFA) reauthorization and requests public comments through December 1, 2027. The AGDUFA program, which funds FDA's review of generic animal drug submissions, expires September 30, 2028 without new legislation. FDA is soliciting input on program performance and suggestions for the next authorization.
FDA DMB Acknowledgment Letter to VIP Lighting NWA
FDA's Center for Devices and Radiological Health (CDRH) issued an acknowledgment letter to VIP Lighting NWA regarding submission FDA-2026-V-3710. The document serves as administrative confirmation of receipt of a filing, though the specific submission details are not publicly viewable in the available record. No regulatory obligations, deadlines, or penalties are stated in the acknowledgment.
FDA Denies Citizen Petition FDA-2025-P-3263 from George W. Murgatroyd III
FDA CDER issued a final response letter denying citizen petition FDA-2025-P-3263 submitted by George W. Murgatroyd III. The petition was denied by the Center for Drug Evaluation and Research. No additional details are available as the document attachments contain personally identifiable information and are not publicly accessible.
FDA Center for Tobacco Products Files Complaint FDA-2026-H-3876
The FDA Center for Tobacco Products (CTP) filed a formal complaint (FDA-2026-H-3876-0001) on April 16, 2026. The complaint document is available as an attachment on Regulations.gov. No additional details about the specific allegations, parties involved, or requested relief are accessible in the available metadata.
FDA Complaint FDA-2026-H-3613 Closed - No Documents Available
The FDA posted a complaint record (FDA-2026-H-3613) on April 17, 2025. The complaint was filed by the Center for Tobacco Products (CTP) and has been closed. No documents are available for public review or download. This is a procedural record indicating closure of an unspecified complaint matter.
Arius Recordings LLC Variance Application
FDA's Center for Devices and Radiological Health (CDRH) received a variance application from Arius Recordings LLC. The application seeks relief or exemption from specific FDA regulatory requirements under 21 CFR. No documents are currently available for public viewing, and the application remains under agency review.
Rural Health Network Development Planning Program Performance Measures OMB Revision
HRSA submitted an Information Collection Request to OMB for review and approval under the Paperwork Reduction Act of 1995. The agency seeks public comments by May 20, 2026, on revised performance measures for the Rural Health Network Development Planning Program. The proposed revision reduces the total number of measures from 24 to 15, consolidating sections into 'Capacity/Organizational Information' and 'Sustainability.' Estimated annual burden is 281.25 hours across 25 respondents at 11.25 hours per response.
Engineered High-Affinity Human T Cell Receptors - EP3071594A1
The European Patent Office published patent application EP3071594A1 for engineered high-affinity human T cell receptors, filed by the Board of Trustees of the University of Illinois. The invention relates to engineered high-affinity human T cell receptors (TCRs) with applications in cancer immunotherapy. The application is classified under C07K 14/725, A61K 38/17, and A61P 35/00, with designation extending to all EU member states plus other European countries.
European Patent for Kava-Derived Therapeutic Compounds and Methods of Use Thereof
EPO granted patent EP3068416A1 to Kuality Herbceutics LLC and 9 named inventors for kava-derived therapeutic compounds and methods of use. The invention is classified under IPC codes A61K 31/12, A61K 31/353, A61K 31/366 (therapeutic compounds) and A61P 35/00 (cancer treatment). The patent is designated in 36 European states including Germany, France, UK, Italy, Spain, Netherlands, Belgium, Austria, and Switzerland.
Bifunctional BTK Degrading Compounds Via Ubiquitin Proteasome Pathway
The European Patent Office published patent EP3924350A1, granted to Nurix Therapeutics, Inc., covering bifunctional compounds for degrading BTK via the ubiquitin proteasome pathway. The patent application includes six IPC classifications spanning pharmaceutical compositions and therapeutic methods. Protection extends across 31 designated European states including major markets.
UPAR Targeting Peptide for Peroperative Optical Imaging of Invasive Cancer
The EPO published patent application EP3733215A1 for Fluoguide A/S, covering a UPAR targeting peptide for peroperative optical imaging of invasive cancer. The patent names Andreas Kjaer and Morten Persson as inventors and includes designations across multiple European member states including DE, FR, GB, IT, ES, NL, and others. This publication grants intellectual property protection for the novel peptide composition and its diagnostic use in cancer surgery.
D3 Receptor Agonist Compounds; Methods of Preparation; Intermediates Thereof; and Methods of Use Thereof
EPO published patent application EP3953350A1 for D3 receptor agonist compounds filed by the United States Department of Health and Human Services. The patent covers specific chemical compounds, methods of preparation, intermediates thereof, and methods of therapeutic use.
Amgen Antigen Binding Proteins Targeting Beta-Klotho and FGF Receptors
The European Patent Office granted Amgen Inc. Patent EP3760642A1 covering human antigen binding proteins that bind beta-Klotho, FGF receptors, and complexes thereof. The patent covers therapeutic applications including treatment of metabolic conditions (A61P 3/04). The patent is designated for all 31 European states including DE, FR, GB, IT, ES, NL, SE, and 21 others.
DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
EPO published patent application EP3930744A1 by Allogene Therapeutics Inc. and Pfizer Inc. for DLL3 targeting chimeric antigen receptors (CARs) and binding agents. The application classified under A61K 39/00, A61P 35/00, and C07K 16/28 covers therapeutic compositions targeting DLL3 for cancer treatment. The patent designates 31 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.
Lonza Ltd Patents Larch Tree Arabinogalactan-Polyphenol Composition
The European Patent Office published patent application EP2638914A1 filed by Lonza Ltd, covering a composition comprising arabinogalactan and polyphenols derived from larch trees. The application, filed by inventors Freitas and Rodriguez, is classified under IPC codes A61K 36/13, A61P 31/00, and A61P 31/12, indicating therapeutic anti-infective applications. The patent designates all EU member states and additional European countries.
Neurotrophin Binding Protein p75NTR for Osteoarthritis Treatment - Patent EP3169347A1
The European Patent Office published patent application EP3169347A1 on April 8, 2026, covering neurotrophin binding protein p75NTR for use in treating osteoarthritis. Applicant Levicept Limited, invented by Simon Westbrook, received European patent protection covering A61K therapeutic compositions. The patent designates all EPC contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
Integrin Alpha10 Patent for Aggressive Cancer Treatment
The European Patent Office published patent application EP3956360A1 for Integrin Alpha10 compositions and methods for treating aggressive cancer forms. Applicant Targinta AB seeks protection across 37 designated European states. The patent covers anti-integrin alpha10 antibodies and therapeutic applications for cancer treatment.
Multiplex Genome Editing of Immune Cells for Enhanced Functionality and Resistance to Suppressive Environment
The USPTO granted patent US12600944B2 to the Board of Regents, The University of Texas System covering methods for multiplex genome editing of immune cells, including disruption of multiple genes and insertion of chimeric antigen receptors at specific gene loci. The patent names Rafet Basar, Elizabeth Shpall, and Katy Rezvani as inventors and contains 14 claims. The filing date was November 27, 2019.
ELTA Patent - Enzymatic ADP-ribose Labeling Methods
USPTO granted patent US12601734B2 to Johns Hopkins University covering ELTA (Enzymatic Labeling of Terminal ADP-ribose) technology for labeling free, protein-conjugated, or nucleic acid-conjugated ADP-ribose molecules at their 2'-OH termini. The patent contains 28 claims and covers applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.
Beta Ketoacyl Synthase IV Variants by CORBION BIOTECH
USPTO granted Patent US12600994B2 to CORBION BIOTECH, INC. covering non-natural variant β-ketoacyl-ACP synthase (KAS) IVa enzymes, polynucleotides encoding such variants, host cells expressing such variants, and oils and oil products produced by such cells. The patent names Joshua Ferreira, Janice Lau Wee, and Nien-Hsi Ko as inventors. Filing date was January 15, 2021, with 21 claims granted.
Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same
USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.
AB Enzymes Xylanase Variants - Patent US12600960B2
The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.
Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells
USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.
US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto
USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.
Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell
USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.
Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine
USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.
Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity
USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.